REVIEW article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1669157
PDE10A as a Novel Diagnostic and Therapeutic Target in Cancer: Insights and Challenges
Provisionally accepted- 1Mashhad University of Medical Sciences, Mashhad, Iran
- 2National Institute of Neurological Disorders and Stroke (NIH), Bethesda, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Phosphodiesterase 10A (PDE10A) is a dual-substrate enzyme that hydrolyzes both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), playing a critical role in regulating intracellular signaling pathways. While its function has been extensively studied in the central nervous system, emerging evidence highlights its broader physiological and pathological relevance, including its involvement in cancer. Functionally, it modulates key signaling pathways such as cAMP/protein kinase A (PKA) and cGMP/protein kinase G (PKG), influencing cell proliferation, differentiation, and apoptosis. In cancer, PDE10A exhibits a context-dependent role. It functions as an oncogene in cancers such as colorectal, ovarian, gastric, and non-small cell lung cancers through overexpression and downstream activation of the Wnt/β-catenin, MAPK/ERK, and PI3K/AKT pathways. Pharmacological inhibition of PDE10A using selective inhibitors has demonstrated potent anti-tumor effects in preclinical models by restoring cyclic nucleotide levels and suppressing oncogenic signaling. Conversely, in glioblastoma (GBM), PDE10A acts as a tumor suppressor, and its knockdown promotes tumor progression via activation of the PI3K/AKT pathway. These findings showed the ability of PDE10A to be considered as a promising biomarker and therapeutic target in oncology; however, it is suggested to examine the tissue-specific expression of PDE10A, baseline cyclic nucleotide levels, cross-talk with other pathways, differences in the degree and duration of PDE10A suppression, and the interplay between PDE10A-mediated cyclic nucleotide signaling and compensatory oncogenic pathways for an effective therapy as observed in other PDEs family reviewed in this manuscript.
Keywords: phosphodiesterase 10A, PDE10A, cyclic adenosine monophosphate, cyclic guanosine monophosphate, Cancer
Received: 19 Jul 2025; Accepted: 03 Oct 2025.
Copyright: © 2025 Ghoflchi, Nakhaei, Jalili-Nik and Cimino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mohammad Jalili-Nik, mohammad.jalilinik@gmail.com
Patrick J Cimino, pjcjpjcj@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.